Sorted By Test Name - Mayo Medical Laboratories

C2729
81413
Useful For: Testing for IgE antibodies may be useful to establish the diagnosis of an allergic disease
and to define the allergens responsible for eliciting signs and symptoms. Testing also may be useful to
identify allergens which may be responsible for allergic disease and/or anaphylactic episode, to confirm
sensitization to particular allergens prior to beginning immunotherapy, and to investigate the specificity of
allergic reactions to insect venom allergens, drugs, or chemical allergens.
Interpretation: Detection of IgE antibodies in serum (Class 1 or greater) indicates an increased
likelihood of allergic disease as opposed to other etiologies and defines the allergens that may be
responsible for eliciting signs and symptoms. The level of IgE antibodies in serum varies directly with the
concentration of IgE antibodies expressed as a class score or kU/L.
Reference Values:
Class IgE kU/L Interpretation
0 Negative
1 0.35-0.69 Equivocal
2 0.70-3.49 Positive
3 3.50-17.4 Positive
4 17.5-49.9 Strongly positive
5 50.0-99.9 Strongly positive
6 > or =100 Strongly positive Reference values
apply to all ages.
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by
Laboratory Methods. 21st edition. Edited by McPherson RA, Pincus MR. WB Saunders, Publ, New York,
2007 Chapter 53, Part VI, pp 961-971
Breast Carcinoma-Associated Antigen (CA 27.29), Serum
Clinical Information: Carcinoma of the breast is the most prevalent form of cancer in women. These
tumors often produce mucinous antigens that are large-molecular-weight glycoproteins with O-linked
oligosaccharide chains. Monoclonal antibodies directed against these antigens have been developed, and
several immunoassays are available to quantitate the levels of tumor-associated mucinous antigens in
serum. The antibodies recognize epitopes of a breast cancer-associated antigen encoded by the human
mucin 1 (MUC-1) gene, which is known by several names including MAM6, milk mucin antigen, CA
27.29, and cancer antigen 15-3 (CA 15-3). While CA 27.29 is expressed at the apical surface of normal
epithelial cells, it is present throughout malignant epithelial cells of the breast, lung, ovary, pancreas, and
other sites. The cancer-associated form of the antigen is less extensively glycosylated than the normal
form and more specific for tumor cells.
Useful For: The FDA has approved CA 27.29 for serial testing in women with prior stage II or III
breast cancer who are clinically free of disease. Predicting early recurrence of disease in women with
treated carcinoma of the breast As an indication that additional tests or procedures should be performed to
confirm recurrence of breast cancer
Interpretation: Increased levels of CA 27.29 (>38 U/mL) may indicate recurrent disease in a woman
with treated breast carcinoma.
Reference Values:
Males
> or =18 years: < or =38.0 U/mL (use not defined)
Females
> or =18 years: < or =38.0 U/mL
Reference values have not been established for patients that are